HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: clinchem.2004.042416v1 51/2/298    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Kösel, S. Articles by Olgemöller, B. Search for Related Content PubMed PubMed Citation Articles by Kösel, S. Articles by Olgemöller, B. Related Collections Molecular Diagnostics and Genetics Pediatric Clinical Chemistry Automation and Analytical Techniques

Rapid Second-Tier Molecular Genetic Analysis for Congenital Adrenal Hyperplasia Attributable to Steroid 21-Hydroxylase Deficiency

¹ Labor Becker, Olgemöller und Kollegen, Munich, Germany.
² Klinik mit Poliklinik für Kinder und Jugendliche, Friedrich-Alexander-Universität, Erlangen, Germany.
³ Dr. von Haunersches Kinderspital, Ludwig-Maximilians-Universität, Munich, Germany.

^aAddress correspondence to this author at: Labor Becker, Olgemöller und Kollegen, Führichstrasse 70, 81671 Munich, Germany. Fax 49-89-450917-300; e-mail b.olgemoeller{at}labor-bo.de.

Background: Neonatal screening for steroid 21-hydroxylase (CYP21) deficiency is performed to identify congenital adrenal hyperplasia (CAH). The immunologic assay for 17-hydroxyprogesterone (17-OHP) has a high rate of false positives. We assessed the potential for increasing the specificity for CAH by use of a second step involving analysis of the CYP21 gene.

Methods: Between January 1999 and December 2003, a total of 810 000 newborns were screened. Of these, 7920 had to be retested because their 17-OHP values were above the cutoff of the assay. Sixty-one had positive 17-OHP values in their recall samples and were diagnosed as having CAH. We used a rapid assay for common mutations of the CYP21 gene to analyze these 61 samples. In a prospective study, 198 consecutive samples that had increased 17-OHP and 100 samples that had normal 17-OHP concentrations were genotyped.

Results: Fifty-nine of 61 cases diagnosed as having CAH were confirmed genetically as CYP21 deficiencies. One patient had a 3ß-hydroxysteroid dehydrogenase deficiency, and one patient carried no CYP21 mutations. The 198 increased 17-OHP results were designated as false positives after immunologic testing of recall samples. None of these samples exhibited the genetic pattern consistent with CYP21 deficiency.

Conclusions: If samples with increased 17-OHP values were screened genetically, the number of retests would decrease by 90%, but the overall sensitivity of CAH screening would remain the same. Adding a second-tier genetic step would require a modest increase in costs, but is counterbalanced by fewer recalls, less clinical follow-up, and a reduction in unnecessary worry for families.

The following articles in journals at HighWire Press have cited this article:

				N. Janzen, M. Peter, S. Sander, U. Steuerwald, M. Terhardt, U. Holtkamp, and J. Sander Newborn Screening for Congenital Adrenal Hyperplasia: Additional Steroid Profile using Liquid Chromatography-Tandem Mass Spectrometry J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2581 - 2589. [Abstract] [Full Text] [PDF]